OIA
ORMP icon

Optimum Investment Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Optimum Investment Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$20K – 951
2021
Q1 		$20K Buy
+2,000
New +$16.4K 0.01% 670

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Optimum Investment Advisors's ORMP Position: Q2 2021 in Review

Optimum Investment Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q2 2021, closing a stake of 2,000 shares — an estimated $20K sold.

Optimum Investment Advisors first reported a position in ORMP in Q1 2021 and held it in 1 quarter. The position peaked at $20K in Q1 2021. 75 funds tracked by Wall St. Rank hold ORMP as of Q2 2021.

  • Optimum Investment Advisors reported no remaining Oramed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Optimum Investment Advisors sold 2,000 Oramed Pharmaceuticals shares in Q2 2021, an estimated $20K.
  • Optimum Investment Advisors first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Optimum Investment Advisors's Oramed Pharmaceuticals position peaked at $20K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2021.

Based on Optimum Investment Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.